A highly potent angiotensin IV analog developed at Washington State University, studied for its role in synaptogenesis and HGF/MET signaling in the brain.
Dihexa is a small molecule peptide derived from angiotensin IV — a fragment of the renin-angiotensin system, which most people associate with blood pressure regulation. Researchers at Washington State University discovered that by modifying this fragment, they created a compound with remarkable activity in the brain, operating through a completely different pathway than the cardiovascular effects people normally associate with angiotensin.
It works through the HGF/MET system — a signaling pathway that promotes synapse formation and neuronal connection growth. This makes it a structurally unusual research compound: it looks like a cardiovascular molecule, but its research interest is almost entirely neurological.
📡 Weekly peptide research updates — regulatory updates, new compound profiles, COA alerts.
⚠️ FDA PCAC: -- days leftNo spam. Unsubscribe anytime. 7 peptides under review — see what's at stake →
Dihexa occupies a unique position in cognitive research: it targets a mechanism (HGF/MET signaling) that most cognitive compounds don't touch, and it does so at concentrations that have surprised researchers with their potency in laboratory models.
7 free research tools built around exactly this kind of compound data. No paywall, no credit card.
Dihexa binds to HGF (Hepatocyte Growth Factor) and facilitates its interaction with the MET receptor. This signaling cascade promotes the formation of dendritic spines — the tiny protrusions on neurons where synaptic connections form and information is exchanged. More spines, more connections; more connections, more capacity for learning and memory encoding.
Imagine neurons are Lego builders who want to connect their creations but keep dropping their connection pieces. HGF is like a helpful assistant who holds the pieces in place so the builders can snap them together. Dihexa might work like a turbo-charged version of that assistant — making it far easier and faster for neurons to form stable, lasting connections before the moment passes.
Research Disclaimer: The following reflects published clinical and preclinical research and is not medical advice. Consult a licensed healthcare provider before making any health decisions.
Dihexa research protocols come exclusively from the McCoy group at Washington State University. No human clinical trials have been conducted. Published data is preclinical — rodent cognitive and memory models with detailed dose-response documentation.
Key References: McCoy AT et al. (2013). Dihexa in aged rat memory impairment. J Pharmacol Exp Ther. · Wright JW & Harding JW (2015). Dihexa HGF/c-Met axis and cognitive function. Physiol Behav.
Dihexa was developed at Washington State University — it's one of the few novel cognitive peptides to emerge from a US academic research program, making it a rare domestically-originated entry in this category.
It works through the HGF/MET pathway — the same signaling system involved in organ development, tissue regeneration, and wound healing. The brain taps into this same ancient system for building and maintaining neural architecture.
At extremely small concentrations (nanomolar range), Dihexa has shown measurable effects on synapse formation in laboratory studies. Researchers are still actively investigating why such tiny amounts produce such significant impacts on neuronal connectivity.
Every batch of Dihexa with full Certificate of Analysis documentation. Third-party HPLC verification, mass spectrometry confirmation, and sterility testing results are included with each batch.